Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
NCT04788511 · View on ClinicalTrials.gov ↗
Study Summary
This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm. During the study participants will have talks with the study staff about healthy lifestyle choices including healthy food and physical activity. The study will last for approximately 59 weeks. Participants will have 11 clinic visits and 1 phone call with the study doctor. Women: Women cannot take part if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
Study Locations (20)
Illinois
- Endeavor Health Clinical Operations-NCH — Arlington Heights
- University of Chicago Medicine — Chicago
- Endeavor Health Glenbook Hosp — Evanston
- Northwestern University_Chicago_0 — Evanston
- Chicago Medical Research LLC — Hazel Crest
Florida
- Jacksonville Ctr For Clin Res — Jacksonville
- First Coast Cardiovascular Institute — Jacksonville
- Baptist Heart Specialists_Jacksonville — Jacksonville
- CV Res Ctr of S Florida — Miami
California
- National Heart Institute Cal — Beverly Hills
- Keck Medical Center of USC - Outpatient Clinic — Los Angeles
- Lundquist Inst-Biomed Innovtn — Torrance
Kentucky
- The Research Group of Lexington LLC — Lexington
- Baptist Health Louisville — Louisville
- Baptist Health Madisonville, Inc — Madisonville
Kansas
- University of Kansas Medical Center_Kansas City — Kansas City
- Cotton-O'Neil Heart Center — Topeka
Alabama
- Eastern Shore Rsrch Inst, LLC — Fairhope
Indiana
- Ascension St. Vincent Medical Group — Indianapolis
Iowa
- University of Iowa — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 529 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2023-04-18 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04788511
The ClinicalTrials.gov registry entry for NCT04788511 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 529 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 189 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which Semaglutide is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04788511 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Illinois, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04788511 about?
NCT04788511 is a clinical study titled "Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity". This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semagluti...
What is the current status of trial NCT04788511?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 529 participants. The study started on 2021-03-16. Estimated completion is 2023-04-18.
What conditions does trial NCT04788511 study?
This clinical trial studies the following conditions: Obesity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04788511?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04788511?
This trial is sponsored by Novo Nordisk A/S, which has 189 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04788511 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.